Diabetes
Refine Search
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Texas-based biopharma Lexicon Pharmaceuticals was trading nearly 36% lower on Friday morning. 1 November 2024
Pharmaceutical
Denmark’s Novo Nordisk bucked a down trending market today, rising 1% on promising research results. 1 November 2024
Pharmaceutical
Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant earlier announced its financial results for the third quarter of 2024, along with its latest guidance for the year as a whole. 31 October 2024
Pharmaceutical
US drugmaker Eli Lilly looked set to lose a whopping $730 million in the stock market value on Wednesday, if its lunchtime position was to be maintained. 30 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
Pharmaceutical
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Pharmaceutical
Canada-based biotech Sernova (TSX: SVA) has announced key new appointments to its executive leadership team. 15 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. 10 October 2024
Generics
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
Pharmaceutical
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Pharmaceutical
Eli Lilly today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. 2 October 2024
Biotechnology
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Pharmaceutical
Danish diabetes care giant Novo Nordisk this morning released financials, showing that sales for the first nine months of 2018 had decreased by 2% in Danish kroner and increased 4% in local currencies to 82.1 billion Danish kroner ($12.52 billion). 1 November 2018
Pharmaceutical
There were plenty of reasons to be cheerful at Sanofi on Wednesday as the company presented its third-quarter results. 31 October 2018
Pharmaceutical
Denmark’s Novo Nordisk and French pharma major Sanofi lead the pack when it comes to delivering a standout online experience to US patients in the crowded marketplace for type 2 diabetes treatments, a study from DRG Digital Manhattan Research reveals. 23 October 2018
Biotechnology
New Jersey’s Merck & Co has reportedly backed away from taking a biosimilar follow-on product to market in the USA, despite already having tentative approval to do so from the US Food and Drug Administration. 15 October 2018
Pharmaceutical
For children and adolescents (1 to 12 October 2018
Pharmaceutical
Eisai has presented data showing the potential of its anti-obesity drug Belviq (lorcaserin hydrochloride) to prevent and cause remission of type 2 diabetes. 5 October 2018
Pharmaceutical
Germany’s Boehringer Ingelheim and the USA’s Eli Lilly have presented positive long-term results from the CARMELINA trial of Tradjenta (linagliptin) at the annual meeting of the European Association for the Study of Diabetes, in Berlin. 5 October 2018
Pharmaceutical
Boehringer Ingelheim and Eli Lilly announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III program in adults with type 1 diabetes. 4 October 2018
Biotechnology
OxStem, an Oxford University spin-out developing regenerative medicine-based therapies, is launching two subsidiary companies to develop regenerative treatments for diabetes and chronic inflammation and wound healing. 4 October 2018
Pharmaceutical
Six month Phase II data on Eli Lilly’s dual GIP and GLP-1 receptor agonist, LY3298176, show “clinically meaningful blood sugar reduction and weight loss” in people with type 2 diabetes, the firm says. 4 October 2018
Biotechnology
At EASD 2018, The Pharma Letter spoke with Novo Nordisk’s chief medical officer Stephen Gough Mads Krogsgaard Thomsen about recent job losses at the company, and the seismic potential of oral semaglutide. 2 October 2018
Biotechnology
London-listed GlaxoSmithKline has presented positive data from the Harmony Outcomes study at the European Association for the Study of Diabetes. 2 October 2018
Pharmaceutical
The 54th annual meeting of the European Association for the Study of Diabetes kicks off in Berlin today, offering a week of data presentations from leading drugmakers in the diabetes space. 2 October 2018
Pharmaceutical
At its annual meeting in Berlin, the European Association for the Study of Diabetes (EASD) has launched a new initiative, aimed at enabling “the sustainability of European healthcare systems to cope with the diabetes pandemic.” 2 October 2018
Biotechnology
Copenhagen-based diabetes giant Novo Nordisk has announced that it will reduce its US workforce by around 250, just two weeks after revealing an R&D overhaul that will see around 400 jobs lost in Denmark and China. 1 October 2018
Pharmaceutical
US pharma major Eli Lill has entered into a license agreement for OWL833, an oral non-peptidic GLP-1 receptor agonist. 27 September 2018
Biotechnology
Texan drugmaker Lexicon Pharmaceuticals has announced details of clinical data for oral diabetes therapy sotagliflozin, to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Biotechnology
Adocia has announced details of five abstracts to be presented at the upcoming annual meeting of the European Association for the Study of Diabetes (EASD). 27 September 2018
Pharmaceutical
Positive results from the Phase III DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for Farxiga (dapagliflozin), the broadest SGLT2 inhibitor CVOT conducted to date have been released today. 24 September 2018
Pharmaceutical
Headline results from PIONEER 10, a Phase IIIa trial with oral semaglutide versus once-weekly subcutaneous dulaglutide, both in combination with one oral antidiabetic drug in Japanese adults with type 2 diabetes. 20 September 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze